


Key facts

	Females	Males	Total
Number of new cases per year	1,157	1,407	2,564
Incidence rate (cases per 100,000 per year)	41.0	55.3	-
Cumulative lifetime risk of diagnosis (to age 74)	1 in 29	1 in 23	-
Percentage of all invasive cancers *	11.1%	11.8%	11.5%
Ranking among most common cancers *	2 nd	3 rd	4 th
Number of deaths per year	785	1,069	1,854
Mortality rate (deaths per 100,000 per year)	28.9	45.9	-
Cumulative lifetime risk of death (to age 74)	1 in 44	1 in 30	-
Percentage of all cancer deaths	19%	22%	21%
Ranking among most common invasive cancer deaths	1 st	1 st	1 st
Number of people with this cancer still alive, end 2015 #	2,650	2,566	5,216
Number alive per 100,000	116	112	112

*Invasive cancers only, excluding non-melanoma skin cancer


#diagnosed since 1994

Cases mapped by county



Annual average number of cases, 2005-2015: colours indicate higher or lower than expected based on national rates


Age profile at diagnosis and death




Top risk factors

- Tobacco smoking
- Passive smoking
 - Radon
- Ionizing radiation
- Arsenic and arsenic compounds; asbestos; beryllium and beryllium compounds; cadmium and cadmium compounds; chromium compounds; nickel compounds; silica dust; and polycyclic aromatic hydrocarbons (PAHs)
 - Employment as a painter
- Beta-carotene supplements in current smokers
 - History of tuberculosis
- Indoor emissions from household combustion of coal
 - Family history of lung cancer

Trend in incidence and mortality



Stage at diagnosis



APC# Incidence: Males (94-15) 2.2%; Females (94-15) -0.8%
Mortality: Males (94-15) -1.9%; Females (94-15) 0.5%
 # Annual Percentage Change

Treatment within 1 year

85%
pathologically
diagnosed

20% Surgery

33%
Chemotherapy

35%
Radiotherapy

% of all cases diagnosed 2013-2015

5 year net survival

Diagnosed	Net Survival (age standardised)	95% Confidence interval
1994-1998	9.0%	8.2-9.7%
1999-2003	9.9%	9.2-10.7%
2004-2008	12.4%	11.6-13.2%
2009-2013	17.9%	16.9-19.0%

*10 year net survival (hybrid analysis):

15.1% (14.0-16.2%)